HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.

AbstractBACKGROUND:
An oral tegafur compound, S-1 (TS-1), was developed to potentiate antitumor activity and to reduce gastrointestinal toxicities for patients with gastric cancer. It has achieved a high response rate against advanced and recurrent gastric cancer (ARGC) in Japan; however, the efficacy and adverse reactions of longterm administration of S-1 remain to be elucidated.
METHODS:
Sixty-nine patients with ARGC treated with S-1 were studied; 58 patients had measurable lesions, while 11 patients did not. S-1 was orally administered at doses of between 40 and 60 mg/body twice daily for 28 days, followed by 14 days' rest, as one course.
RESULTS:
The overall response rate was 38% (complete response [CR], 2/58; partial response [PR], 25/58; stable disease [SD], 9/58 progressive disease [PD] 23/58). Response rate by target organ was 40% for the primary lesion, 45% for lymph node metastasis, 38% for peritoneal metastasis, and 25% for liver metastasis. When S-1 was administered as second-line chemotherapy (n = 25), the response rate was 36%. Of the 69 patients, 14 received S-1 for more than a year. The median survival time (MST) after S-1 administration in these 14 patients, including 3 patients with stable disease, was 918 days (range, 536 to 1107 days). There were no grade 3 to 4 toxicities in these 14 patients receiving longterm therapy with S-1.
CONCLUSION:
S-1 therapy was performed with a high response rate, irrespective of the target organ or the presence of prior chemotherapy. Longterm administration of S-1 may benefit patients with ARGC, providing prolonged disease control with acceptable toxicities.
AuthorsHaruhiko Cho, Kazuo Konishi, Akira Tsuburaya, Osamu Kobayashi, Motonori Sairenji, Hisahiko Motohashi, Toshio Imada
JournalGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (Gastric Cancer) Vol. 6 Suppl 1 Pg. 24-7 ( 2003) ISSN: 1436-3291 [Print] Japan
PMID12775016 (Publication Type: Evaluation Studies, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • Pyridines
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic (administration & dosage, adverse effects)
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Japan (epidemiology)
  • Liver Neoplasms (drug therapy, secondary)
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy, mortality)
  • Oxonic Acid (administration & dosage, adverse effects)
  • Peritoneal Neoplasms (drug therapy, secondary)
  • Pyridines (administration & dosage, adverse effects)
  • Severity of Illness Index
  • Stomach Neoplasms (drug therapy, mortality)
  • Survival Analysis
  • Tegafur (administration & dosage, adverse effects)
  • Time
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: